thyroid cancers
Recently Published Documents


TOTAL DOCUMENTS

754
(FIVE YEARS 190)

H-INDEX

49
(FIVE YEARS 8)

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 357
Author(s):  
Caitlin E. M. Thornton ◽  
Jingzhu Hao ◽  
Prasanna P. Tamarapu ◽  
Iñigo Landa

Hotspot mutations in the TERT (telomerase reverse transcriptase) gene are key determinants of thyroid cancer progression. TERT promoter mutations (TPM) create de novo consensus binding sites for the ETS (“E26 transformation specific”) family of transcription factors. In this study, we systematically knocked down each of the 20 ETS factors expressed in thyroid tumors and screened their effects on TERT expression in seven thyroid cancer cell lines with defined TPM status. We observed that, unlike in other TPM-carrying cancers such as glioblastomas, ETS factor GABPA does not unambiguously regulate transcription from the TERT mutant promoter in thyroid specimens. In fact, multiple members of the ETS family impact TERT expression, and they typically do so in a mutation-independent manner. In addition, we observe that partial inhibition of MAPK, a central pathway in thyroid cancer transformation, is more effective at suppressing TERT transcription in the absence of TPMs. Taken together, our results show a more complex scenario of TERT regulation in thyroid cancers compared with other lineages and suggest that compensatory mechanisms by ETS and other regulators likely exist and advocate for the need for a more comprehensive understanding of the mechanisms of TERT deregulation in thyroid tumors before eventually exploring TPM-specific therapeutic strategies.


2022 ◽  
Vol 34 (1) ◽  
pp. 26-28
Author(s):  
Reem ElSheikh ◽  
Spyridoula Maraka
Keyword(s):  

2021 ◽  
Author(s):  
Min Kyoung Lee ◽  
Jung Hwan Baek ◽  
Sae Rom Chung ◽  
Young Jun Choi ◽  
Jeong Hyun Lee ◽  
...  

2021 ◽  
Author(s):  
Caitlin E.M. Thornton ◽  
Jingzhu Hao ◽  
Prasanna P. Tamarapu ◽  
Iñigo Landa

AbstractHotspot mutations in the TERT (telomerase reverse transcriptase) gene are key determinants of thyroid cancer progression. TERT promoter mutations (TPM) create de novo consensus binding sites for the ETS (“E26 transforming sequence”) family of transcription factors. In this study, we systematically knocked down each of the 20 ETS factors expressed in thyroid tumors and screened their effects on TERT expression in seven thyroid cancer cell lines with defined TPM status. We observed that, unlike in other TPM-carrying cancers such as glioblastomas, ETS factor GABPA does not unambiguously regulate transcription from the TERT mutant promoter in thyroid specimens. In fact, multiple members of the ETS family impact TERT expression, and they typically do so in a mutation-independent manner. In addition, we observe that partial inhibition of MAPK, a central pathway in thyroid cancer transformation, is more effective at suppressing TERT transcription in the absence of TPMs. Taken together, our results show a more complex scenario of TERT regulation in thyroid cancers compared to other lineages, suggest that compensatory mechanisms by ETS and other regulators likely exist and advocate for the need of a more comprehensive understanding of the mechanisms of TERT deregulation in thyroid tumors before eventually exploring TPM-specific therapeutic strategies.Graphical Abstract


2021 ◽  
pp. 204-210
Author(s):  
Hian Liang Huang ◽  
Kelvin Loke Siu Hoong ◽  
Sumbul Zaheer ◽  
David Ng Chee Eng

2021 ◽  
pp. 155-162
Author(s):  
Emre Divarci ◽  
Ahmet Çelik
Keyword(s):  

2021 ◽  
pp. 014556132110601
Author(s):  
Yuan-Chin Hsu ◽  
Chuen Hsueh ◽  
Wan-Ni Lin ◽  
Tsung-You Tsai ◽  
Shih-Yuan Hung ◽  
...  

Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor that accounts for 0.1%–0.15% of all thyroid cancers. More than half of the patients have tumor extension to adjacent organs, including the recurrent laryngeal nerve, trachea, and esophagus. The diagnosis of CASTLE is based on histology and immunohistochemistry. A 58-year-old female patient complained of hoarseness for one and half years. Right side vocal cord palsy was diagnosed by fiberscopy. Thyroid sonography revealed right thyroid tumors, which were reported to be papillary thyroid carcinoma through FNAC. Total thyroidectomy with central lymph node dissection was performed. Pathologist found 2 isolated malignancy tumors. One patient in the right thyroid lobe had papillary thyroid carcinoma features. The other extrathyroid tumor seemed to be separated from the first tumor and invaded the thyroid capsule. After multiple immunohistochemical studies, PTC synchronous CASTLE was the final diagnosis. Coexisting PTC and CASTLE is very rare. This is the first report to describe a case showing PTC at first, while subsequent pathologic examination revealed the presence of CASTLE in addition to PTC. Since the prognosis of CASTLE is favorable, the treatment is different from other aggressive thyroid cancers, such as poorly differentiated or anaplastic thyroid carcinoma.


2021 ◽  
Author(s):  
Markus Eszlinger ◽  
Paul Stewardson ◽  
John B. McIntyre ◽  
Adrian Box ◽  
Moosa Khalil ◽  
...  

Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from TRK or RET inhibitors. Methods: Patients were identified in the Calgary prospective thyroid cancer database (N=482). Patients were “pre-screened” with clinically available MassARRAY® BRAF Test, Colon Panel, Melanoma Panel, or ThyroSPEC™. Mutation-negative tumors were “screened” for NTRK fusions and RET fusions/mutations with the Oncomine™ Comprehensive Assay v3 (OCAv3). Results: A total of 86 patients were included in one of two separate analyses. Analysis A included 42 patients with radioactive iodine (RAI)-resistant distant metastases. After pre-screening, 20 BRAF and RAS mutation-negative patients underwent OCAv3 screening, resulting in the detection of four patients with NTRK fusions and four patients with RET fusions (8/20, 40% of analyzed patients). Analysis B included 44 patients, 42 with American Thyroid Association (ATA) high and intermediate risk of recurrence and two with medullary thyroid carcinoma. During pre-screening one patient with an NTRK fusion, one patient with a RET fusion and 30 patients with BRAF mutations were identified. The remaining nine patients received OCAv3 screening, resulting in detection of one patient with an NTRK fusion and one with a RET fusion (4/11, 36% of analyzed patients). Conclusions: Our findings indicate a high rate of NTRK fusions and RET fusions in patients with thyroid cancer with RAI-resistant distant metastases, ATA high/intermediate risk of recurrence. This highlights the importance of early screening, to enable intervention with a TRK or RET inhibitor.


2021 ◽  
Vol 37 (2) ◽  
pp. 1-9
Author(s):  
Seonyoung Min ◽  
Hyunseok Kang

Thyroid cancer refers to various cancers arising from thyroid gland. Differentiated thyroid cancers (DTCs) include papillary, follicular, and Hurthle cell carcinomas and represent cancers retain normal thyroid functions such as iodine uptake. Radioactive iodine (RAI) is generally used for upfront treatment of metastatic DTCs, but RAI refractory DTCs remain to be clinical challenges. Sorafenib and lenvatinib were approved for the treatment of RAI refractory DTCs and more recently, genomics-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs. Poorly differentiated and anaplastic thyroid cancers (ATCs) are extremely challenging diseases with aggressive courses. BRAF/MEK inhibition has been proven to be highly effective in BRAF V600E mutation-positive ATCs and immune checkpoint inhibitors have shown promising activities. Medullary thyroid cancers, which arise from parafollicular cells of thyroid, represent a unique subset of thyroid cancer and mainly driven by RET mutation. In addition to vandetanib and cabozantinib, highly specific RET inhibitors such as selpercatinib and pralsetinib have demonstrated impressive activity and are in clinical use.


Sign in / Sign up

Export Citation Format

Share Document